Martin Capital Advisors’s Quest Diagnostics DGX Stock Holding History

Martin Capital Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$667K	Hold	3,145	–	–	0.35%	50
2026 Q1	$616K	Hold	3,145	–	–	0.39%	46
2025 Q4	$546K	Hold	3,145	–	–	0.32%	51
2025 Q3	$599K	Hold	3,145	–	–	0.36%	47
2025 Q2	$565K	Hold	3,145	–	–	0.37%	47
2025 Q1	$532K	Hold	3,145	–	–	0.38%	46
2024 Q4	$474K	Hold	3,145	–	–	0.31%	50
2024 Q3	$488K	Hold	3,145	–	–	0.35%	48
2024 Q2	$430K	Hold	3,145	–	–	0.32%	49
2024 Q1	$419K	Hold	3,145	–	–	0.33%	53
2023 Q4	$434K	Hold	3,145	–	–	0.37%	50
2023 Q3	$383K	Hold	3,145	–	–	0.37%	48
2023 Q2	$442K	Buy	3,145 +130	+4%	+$17.9K	0.4%	47
2023 Q1	$427K	Sell	3,015 -100	-3%	-$14.3K	0.44%	45
2022 Q4	$487K	Buy	3,115 +1,000	+47%	+$144K	0.54%	42
2022 Q3	$259K	Sell	2,115 -2,000	-49%	-$263K	0.38%	51
2022 Q2	$547K	Hold	4,115	–	–	0.48%	46
2022 Q1	$563K	Hold	4,115	–	–	0.39%	47
2021 Q4	$712K	Buy	+4,115	New	+$626K	0.44%	45

Other funds holding DGX

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

CPC

Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return

AIM

Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Martin Capital Advisors's DGX Position: Q2 2026 in Review

Martin Capital Advisors held its Quest Diagnostics (DGX) position steady in Q2 2026 at 3,145 shares worth $667K. The position accounts for 0.35% of the portfolio, ranked #50.

Martin Capital Advisors first reported a position in DGX in Q4 2021 and has held it in 19 quarters since. The position peaked at $712K in Q4 2021. 424 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Martin Capital Advisors held 3,145 shares of Quest Diagnostics worth $667K as of Q2 2026.
Martin Capital Advisors left its Quest Diagnostics share count unchanged in Q2 2026.
Quest Diagnostics made up 0.35% of Martin Capital Advisors's portfolio in Q2 2026, its #50 holding.
Martin Capital Advisors first reported a position in Quest Diagnostics in Q4 2021 and has held it in 19 quarters since.
Martin Capital Advisors's Quest Diagnostics position peaked at $712K in Q4 2021.
424 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Martin Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.